

Advanced analytics.
Intelligent insights.

AI Data Analytics in Neurological Disease

Giulio Cerroni, CEO

AIM: IXI

Disclaimer



This presentation is incomplete without reference to, and should be viewed solely in conjunction with the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which includes certain information drawn from public sources does not purport to be comprehensive and has not been independently verified. It has been prepared and issued by and is the sole responsibility of the Company.

No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors, directors, officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in this presentation or in any revision of the presentation or of any other written or oral information made or to be made available to any information or opinions (which should not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from this presentation or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice.

In particular, this presentation may contain certain forward looking statements that are subject to the usual risk factors. Whilst the Company believes the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome may be materially different owing to factors beyond the Company's control or with in the Company's control where, for example the Company decides on a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potential forward-looking statements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financial projections or other forward looking statements, any assumptions underlying them, the future operations or the amount of any future income or loss.

The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer to purchase or subscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or an invitation or an inducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or be relied on in connection with any contract therefore. This presentation does not constitute an invitation to effect any transaction with the Company or to make use of any services provided by the Company. Reliance on the information contained in this presentation for the purposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about the investment in business to which this presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.


By attending the presentation, or reading or accepting this document you agree to be bound by the foregoing limitations.

IXICO plc is incorporated in England with registered number 3131723 and registered address 15 Long Lane, London, EC1A 9PN.


Bringing clarity to brain imaging through AI



Proprietary AI for accurate 3D segmentation to measure volumes of regions of interest in the brain



IXICO's LEAP ALGORITHM



Artificial Intelligence is not new

Artificial Intelligence

Any technique which enables computers to mimic human behaviour



1950's

1960's

1970's

Machine learning

AI techniques that give computer the ability to learn without being explicitly programmed to do so



1980's

1990's

2000's

Deep learning

A subset of ML which make the computation of multi-layer neural networks feasible



2010's

Advances in AI are accelerating thanks to increases in compute power and the wider availability of large datasets

Leveraging AI is not a differentiator but a “must have” for advanced data analysis

Domain know-how and *contextualized* data create unique value

Unique capabilities combining to create a scalable technology services model



Neuroscience domain knowledge

Dementia




Rare disease



Psychiatry & Mental Health



State of the art technology



AI

Data Platform

Contextualised data

Past and present trials

**Scientific partnerships
Natural history studies**

**IXICO-sponsored
studies**


Drug development costs are high and increasing; dementia represents a significant unmet clinical need




Cost of bringing a drug to market^[1]



US NIH funding for dementia research^[2]



VC, Angel & Pharma investment in neuroscience start-ups^[3]



Development

Medicines in
development
for neurological
diseases^[4]

1,300
2nd largest



**Dementia is the
only major
cause
of death we can't
prevent, slow
down or cure^[5]**

Ageing population

The number of
people in the world
with dementia is
expected to

**triple
by 2050^[2]**



Total worldwide cost of dementia^[6]



[1] Tufts Center for the study of drug development [2] The World Alzheimer Report 2015, *The Global Impact of Dementia*
[3] Clarivate Analytics - Neuroscience Investment [4] PhMRA Biopharmaceutical research industry, 2016 profile
[5] World dementia council, *Defeating dementia: the road to 2025* [6] The World Alzheimer Report 2018, ADI, London

Investment case



01

Strong trading and future revenue visibility from contracted order book

02

Scalable business model operating in an attractive market

03

Proven, adaptive innovation

04



\$31Bn CNS Clinical R&D spend

Lower risk investment in Pharma pipeline

05

Management with a proven track record of delivering growth

3 years' track record of growth



5-point growth strategy

01

Focus on delivering scale and operational excellence

02

Accelerate penetration of clinical trials market; diversify into new indications

03

Target early phase to grow into later clinical phases

04

Innovate: AI machine-learning data analytics

05

Enhance organic growth through selective partnerships and M&A



... to deliver sustained double digit profitable growth

Leadership team



Marcus Thornton
(Jun '18)
Chief Operating Officer



Sylke Grootenk
(Jun '14)
SVP PMO



Grant Nash
(April '19)
Chief Financial Officer



Giulio Cerroni
(Feb '17)
Chief Executive Officer



Alison Howie
(Jun '18)
Chief Product Officer



Robin Wolz
(Mar '14)
SVP Science & Innovation





Lammert Albers
(Oct '19)
Chief Business Officer

New institutional shareholders

Shareholder	Date acquired	No. of Shares	% allocation
BGF Investment Management	May-19	9,354,000	20%
Octopus Investments	May-18	6,708,400	14%
Gresham House	May-18	5,357,100	11%
Canaccord Genuity Group	May-19	5,118,149	11%
Amati Global Investors	May-18	5,031,300	11%
Total major shareholding:			67%

Investment in CNS is increasing



Number of trials in each therapeutic area and % change 2015 to 2018


Continued investment in CNS pipeline, driven by new therapeutic approaches, an ageing population and new types of data which improve the understanding of CNS disease

Biopharma is investing in neuro; emerging biotechs fuelling early pipeline



	Early Phase	Late Phase
Dementia	AbbVie, Biogen, Boehringer Ingelheim, Lilly, Novartis, Roche, Sanofi, Takeda, UCB, AC Immune, Alkahest, Araclon, Axon, Denali, Oryzon, Sunovion, United Neuroscience, Vivoryon, Vaccinex...	Roche, Lilly, AbbVie, Biogen, Novartis, Green Valley
Rare Neuro	Biogen, Novartis, Roche, Takeda, UCB, Asceneuron, Biohaven, Uniqure, Vaccinex, Voyager, Wave Therapeutics,	Roche, Biogen
Psychiatry & Mental Health	Biogen, Boehringer Ingelheim, MSD, Otsuka, Roche, BioXel, Concert pharma, Sunovion...	Roche, UCB, J&J

Growth: Long-term client relationships provide revenue visibility



Future opportunities through investment in AI development & data acquisition



Neuroscience domain knowledge

Faster algorithm development cycles allow the ingestion of more data and testing of more hypotheses



Days to hours to test new approaches

State of the art technology

Greater accuracy through improved models allowing development of more complex biomarkers



25% increase in usable clinical trial data

Process automation to reduce costs; improving margin and offering greater service levels to clients



New fully automated pipelines in production

Contextualised data

Increasing data volumes and diversity



Unique assets to generate greater disease insights and fuel future product development

Ready to scale

01

Sixth consecutive reporting period reporting +20% revenue growth

02

Expanding franchise with blue-chip biopharma client base, driving quality earnings

03

Visibility to future revenues from large contracted order book & strong pipeline

04

Delivering operational gearing and executing operational efficiencies

05

Profitable & well capitalised; continued delivery of sustained, profitable growth



Investing to scale the business for long-term value